Literature DB >> 17269931

Pharmacogenetics and drug therapy in psychiatry--the role of the CYP2D6 polymorphism.

P Vandel1, J M Talon, E Haffen, D Sechter.   

Abstract

The importance of pharmacogenetics in medicine is growing with the identification of genetic variability by faster screening methods using automatic sequencers. A particularly interesting finding is that apart from environmental and psychological factors, drug response may be influenced by several biological factors as a result of genetic determinants leading to interindividual variability. Several mutations in genes coding for enzymes of the drug metabolizing system, as well as for neurotransmitter receptors or degrading enzymes and monoamine transport proteins, have been identified and investigated in psychiatry. But, despite the fact that some genetic polymorphisms of enzymes (mainly cytochrome P450 2D6) are well known, the application of pharmacogenetics as a therapeutic tool for improving patient care is rare. This review has three parts. In the first an overview is given of CYP450 characteristics and the genetic polymorphisms of interest to psychiatry. In the second the clinical implications of the CYP2D6 polymorphism are reviewed and in the third part other aspects on pharmacogenetic research in psychiatry are discussed. The aim of our review is to promote the application of pharmacogenetics in everyday clinical practice.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17269931     DOI: 10.2174/138161207779313704

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  5 in total

1.  Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver.

Authors:  Xia Yang; Bin Zhang; Cliona Molony; Eugene Chudin; Ke Hao; Jun Zhu; Andrea Gaedigk; Christine Suver; Hua Zhong; J Steven Leeder; F Peter Guengerich; Stephen C Strom; Erin Schuetz; Thomas H Rushmore; Roger G Ulrich; J Greg Slatter; Eric E Schadt; Andrew Kasarskis; Pek Yee Lum
Journal:  Genome Res       Date:  2010-06-10       Impact factor: 9.043

2.  Pharmacogenetics, pharmacogenomics and personalized psychiatry: are we there yet?

Authors:  K Broich; H J Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-03       Impact factor: 5.270

3.  Alternative reliable method for cytochrome P450 2D6 poor metabolizers genotyping.

Authors:  E Pindurová; A Zourková; J Zrůstová; J Juřica; A Pavelka
Journal:  Mol Biotechnol       Date:  2013-01       Impact factor: 2.695

Review 4.  Indicators of buprenorphine and methadone use and abuse: what do we know?

Authors:  Jane Carlisle Maxwell; Elinore F McCance-Katz
Journal:  Am J Addict       Date:  2010 Jan-Feb

5.  Potential role of CYP2D6 in the central nervous system.

Authors:  Jie Cheng; Yueying Zhen; Sharon Miksys; Diren Beyoğlu; Kristopher W Krausz; Rachel F Tyndale; Aiming Yu; Jeffrey R Idle; Frank J Gonzalez
Journal:  Xenobiotica       Date:  2013-04-25       Impact factor: 1.908

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.